These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 23776209)

  • 1. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis.
    Wang F; Sambandan D; Halder R; Wang J; Batt SM; Weinrick B; Ahmad I; Yang P; Zhang Y; Kim J; Hassani M; Huszar S; Trefzer C; Ma Z; Kaneko T; Mdluli KE; Franzblau S; Chatterjee AK; Johnsson K; Mikusova K; Besra GS; Fütterer K; Robbins SH; Barnes SW; Walker JR; Jacobs WR; Schultz PG
    Proc Natl Acad Sci U S A; 2013 Jul; 110(27):E2510-7. PubMed ID: 23776209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes.
    Liu R; Lyu X; Batt SM; Hsu MH; Harbut MB; Vilchèze C; Cheng B; Ajayi K; Yang B; Yang Y; Guo H; Lin C; Gan F; Wang C; Franzblau SG; Jacobs WR; Besra GS; Johnson EF; Petrassi M; Chatterjee AK; Fütterer K; Wang F
    Angew Chem Int Ed Engl; 2017 Oct; 56(42):13011-13015. PubMed ID: 28815830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
    Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
    Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.
    Wang P; Batt SM; Wang B; Fu L; Qin R; Lu Y; Li G; Besra GS; Huang H
    J Med Chem; 2021 May; 64(9):6241-6261. PubMed ID: 33852302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.
    Chopra S; Matsuyama K; Tran T; Malerich JP; Wan B; Franzblau SG; Lun S; Guo H; Maiga MC; Bishai WR; Madrid PB
    J Antimicrob Chemother; 2012 Feb; 67(2):415-21. PubMed ID: 22052686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
    Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
    Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France.
    Genestet C; Hodille E; Berland JL; Ginevra C; Bryant JE; Ader F; Lina G; Dumitrescu O;
    Int J Antimicrob Agents; 2020 Apr; 55(4):105912. PubMed ID: 31991222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
    Williams JT; Haiderer ER; Coulson GB; Conner KN; Ellsworth E; Chen C; Alvarez-Cabrera N; Li W; Jackson M; Dick T; Abramovitch RB
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
    Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA.
    McNeil MB; Dennison D; Shelton C; Flint L; Korkegian A; Parish T
    Tuberculosis (Edinb); 2017 Dec; 107():133-136. PubMed ID: 29050761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
    Panda M; Ramachandran S; Ramachandran V; Shirude PS; Humnabadkar V; Nagalapur K; Sharma S; Kaur P; Guptha S; Narayan A; Mahadevaswamy J; Ambady A; Hegde N; Rudrapatna SS; Hosagrahara VP; Sambandamurthy VK; Raichurkar A
    J Med Chem; 2014 Jun; 57(11):4761-71. PubMed ID: 24818517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
    Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
    J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
    Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK
    J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
    Sullivan TJ; Truglio JJ; Boyne ME; Novichenok P; Zhang X; Stratton CF; Li HJ; Kaur T; Amin A; Johnson F; Slayden RA; Kisker C; Tonge PJ
    ACS Chem Biol; 2006 Feb; 1(1):43-53. PubMed ID: 17163639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
    Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
    Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
    Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
    Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
    Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bactericidal therapy in patients with tuberculosis].
    Krasnov VA; Ursov IG
    Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
    [No Abstract]   [Full Text] [Related]  

  • 19. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial drugs: hitting the tuberculosis wall.
    Harrison C
    Nat Rev Drug Discov; 2013 Aug; 12(8):578-9. PubMed ID: 23903215
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.